Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04281667
Other study ID # 14112018
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date March 18, 2020
Est. completion date October 10, 2027

Study information

Verified date November 2022
Source Helsinki University Central Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MOBILE2 is a randomized controlled trial comparing mechanical and oral antibiotic bowel preparation to mechanical bowel preparation only in patients undergoing anterior rectal resection with primary anastomosis. Primary endpoint is Comprehensive Complication Index within 30 days from surgery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 604
Est. completion date October 10, 2027
Est. primary completion date November 9, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients scheduled for anterior rectal resection with primary anastomosis Exclusion Criteria: - Emergency operation - Bowel obstruction - Existing stoma - Other reason preventing mechanical bowel preparation - Allergy to neomycin or metronidazole - Age < 18 years - Lack of co-operation Exclusion criteria after randomization: - Patient did not undergo surgery - Anterior resection was not performed - Colonic anastomosis was not performed

Study Design


Intervention

Drug:
Oral Antibiotics
Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
Placebo
Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
Mechanical Bowel Preparation
Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)

Locations

Country Name City State
Finland Helsinki University Hospital Helsinki
Finland Tampere University Hospital Tampere
Finland Turku University Hospital Turku

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other 5-year overall survival 5-year overall survival 5 years from surgery
Other 5-year disease specific survival 5-year disease specific survival 5 years from surgery
Other 5-year recurrence free survival 5-year recurrence free survival 5 years from surgery
Other Quality of life (SF-36) Difference in quality of life between baseline and 1 year measured using SF-36 At randomization and at one year from surgery
Other Quality of life (QLQ-C30) Difference in quality of life between baseline and 1 year measured using QLQ-C30 At randomization and at one year from surgery
Other Quality of life (QLQ-CR29) Difference in quality of life between baseline and 1 year measured using QLQ-CR29 At randomization and at one year from surgery
Other Quality of life (LARS) Difference in quality of life between baseline and 1 year measured using LARS At randomization and at one year from surgery
Other Adverse effects of antibiotics Adverse effects of antibiotics Within 30 days from surgery
Other Bowel microbiota Bowel microbiota Before, at, 6 months, and 1 year after surgery.
Primary Comprehensive Complication Index Comprehensive Complication Index score Within 30 days from surgery
Secondary Surgical Site Infection Surgical site infection as defined by CDC Within 30 days from surgery
Secondary Anastomotic dehiscence Anastomotic dehiscence Within 30 days from surgery
Secondary Lenght of hospital stay Lenght of hospital stay Within hospital stay, estimated on average 7 days
Secondary Mortality Mortality Within 90 days from surgery
Secondary Adjuvant therapy Patients receiving adjuvant therapy divided by patients needing adjuvant therapy Within 6 months from surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A